Dialyzable leukocyte extracts contain thymosin.
Wilson. G B GB; Paddock. G V GV; Floyd. E E; Newell. R T RT; Dopson. M H MH
Key Findings
- Human dialyzable leukocyte extracts contain thymosin‑alpha‑1
- Thymosin‑alpha‑1 speeds up regeneration of T‑cell E‑receptors after trypsin removal
- In vitro, thymosin‑alpha‑1 increased E‑rosetting T‑cells in two immunodeficient patients
Practical Outcomes
- For biohackers, the study hints that thymosin‑alpha‑1 could have immune‑supporting properties, but the evidence is limited to cell experiments and a very small patient sample, with no dosing or safety guidance, so it isn’t ready for practical self‑use.
Summary
The paper shows that a peptide called thymosin‑alpha‑1, found in certain leukocyte extracts, can help T‑cells rebuild a specific surface receptor and may boost immune activity in a couple of patients with immune deficiency, but the work is early‑stage lab work, not a clinical protocol.
Abstract
Trypsinization of human T-lymphocytes removes surface receptors which bind to sheep erythrocytes (E). Human dialyzable leukocytes extracts (DLE) and thymosin (Fraction V) have been shown to significantly increase the rate of regeneration of T-lymphocyte E-receptors. Both physical-chemical and immunochemical results reported herein indicate that the enhancing effect of human DLE preparations on the rate of regeneration of T-lymphocyte E-receptors is due at least in part to the presence of thymosin alpha 1-peptide in these preparations. Thymosin alpha 1-peptide purified from thymosin Fraction V and putative thymosin alpha 1 preparations purified from human DLEs were each active not only in increasing the rate of regeneration of T-lymphocyte E-receptors removed by trypsinization but also were active in vitro in markedly increasing the number of E-rosetting cells in two patients with immunodeficiency disease manifested in part as a reduction in the normal percentage of mature T-lymphocytes capable of forming E-rosettes.
Study Information
pubmed
1984